Claire E H Barber1, Deborah A Marshall1, Nanette Alvarez1, G B John Mancini1, Diane Lacaille1, Stephanie Keeling1, J Antonio Aviña-Zubieta1, Dmitry Khodyakov1, Cheryl Barnabe1, Peter Faris1, Alexa Smith1, Raheem Noormohamed1, Glen Hazlewood1, Liam O Martin1, John M Esdaile1. 1. From the Division of Rheumatology, Department of Medicine, and the Department of Community Health Sciences, Arthur J.E. Child Chair in Rheumatology Research, the Division of Cardiology and the Department of Cardiovascular Sciences, and the Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta; Division of Cardiology and Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver; Arthritis Research Centre of Canada, Richmond, British Columbia; The RAND Corporation, Santa Monica, California, USA; Division of Rheumatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of International Health, Johns Hopkins University School of Public Health, Baltimore, Maryland, USA.C.E. Barber, MD, FRCPC, PhD Candidate, Division of Rheumatology, Department of Medicine; D.A. Marshall, MHSA, PhD, Associate Professor, Department of Community Health Sciences, Arthur J.E. Child Chair in Rheumatology Research; N. Alvarez, MD, FRCPC, BA, Associate Professor, Division of Cardiology, Department of Cardiovascular Sciences, and Libin Cardiovascular Institute of Alberta, University of Calgary; G.B. Mancini, MD, FRCPC, Professor, Division of Cardiology; D. Lacaille, MD, FRCPC, MHSc, Professor, Division of Rheumatology, Department of Medicine, University of British Columbia and Senior Scientist, Arthritis Research Centre of Canada; S. Keeling, MD, FRCPC, MSc, Associate Professor, Division of Rheumatology, Department of Medicine, University of Alberta; J.A. Aviña-Zubieta, MD, MSc, PhD, Assistant Professor, Division of Rheumatology, Department of Medicine, University of British Columbia and Research Scientist, Arthritis Research Centre of Canada; D. Khodyakov, PhD, MA, Social/Behavioral Scientist, The RAND Corporation; C. Barnabe, MD, FRCPC, MSc, Assistant Professor, Division of Rheumatology, Department of Medicine, Department of Community Health Sciences, University of Calgary and ARC Research Sci
Abstract
OBJECTIVE: Patients with rheumatoid arthritis (RA) have a high risk of premature cardiovascular disease (CVD). We developed CVD quality indicators (QI) for screening and use in rheumatology clinics. METHODS: A systematic review was conducted of the literature on CVD risk reduction in RA and the general population. Based on the best practices identified from this review, a draft set of 12 candidate QI were presented to a Canadian panel of rheumatologists and cardiologists (n = 6) from 3 academic centers to achieve consensus on the QI specifications. The resulting 11 QI were then evaluated by an online modified-Delphi panel of multidisciplinary health professionals and patients (n = 43) to determine their relevance, validity, and feasibility in 3 rounds of online voting and threaded discussion using a modified RAND/University of California, Los Angeles Appropriateness Methodology. RESULTS: Response rates for the online panel were 86%. All 11 QI were rated as highly relevant, valid, and feasible (median rating ≥ 7 on a 1-9 scale), with no significant disagreement. The final QI set addresses the following themes: communication to primary care about increased CV risk in RA; CV risk assessment; defining smoking status and providing cessation counseling; screening and addressing hypertension, dyslipidemia, and diabetes; exercise recommendations; body mass index screening and lifestyle counseling; minimizing corticosteroid use; and communicating to patients at high risk of CVD about the risks/benefits of nonsteroidal antiinflammatory drugs. CONCLUSION: Eleven QI for CVD care in patients with RA have been developed and are rated as highly relevant, valid, and feasible by an international multidisciplinary panel.
OBJECTIVE:Patients with rheumatoid arthritis (RA) have a high risk of premature cardiovascular disease (CVD). We developed CVD quality indicators (QI) for screening and use in rheumatology clinics. METHODS: A systematic review was conducted of the literature on CVD risk reduction in RA and the general population. Based on the best practices identified from this review, a draft set of 12 candidate QI were presented to a Canadian panel of rheumatologists and cardiologists (n = 6) from 3 academic centers to achieve consensus on the QI specifications. The resulting 11 QI were then evaluated by an online modified-Delphi panel of multidisciplinary health professionals and patients (n = 43) to determine their relevance, validity, and feasibility in 3 rounds of online voting and threaded discussion using a modified RAND/University of California, Los Angeles Appropriateness Methodology. RESULTS: Response rates for the online panel were 86%. All 11 QI were rated as highly relevant, valid, and feasible (median rating ≥ 7 on a 1-9 scale), with no significant disagreement. The final QI set addresses the following themes: communication to primary care about increased CV risk in RA; CV risk assessment; defining smoking status and providing cessation counseling; screening and addressing hypertension, dyslipidemia, and diabetes; exercise recommendations; body mass index screening and lifestyle counseling; minimizing corticosteroid use; and communicating to patients at high risk of CVD about the risks/benefits of nonsteroidal antiinflammatory drugs. CONCLUSION: Eleven QI for CVD care in patients with RA have been developed and are rated as highly relevant, valid, and feasible by an international multidisciplinary panel.
Authors: Rita Mangione-Smith; Alison H DeCristofaro; Claude M Setodji; Joan Keesey; David J Klein; John L Adams; Mark A Schuster; Elizabeth A McGlynn Journal: N Engl J Med Date: 2007-10-11 Impact factor: 91.245
Authors: B J Radovits; J Fransen; S Al Shamma; A M Eijsbouts; P L C M van Riel; R F J M Laan Journal: Arthritis Care Res (Hoboken) Date: 2010-03 Impact factor: 4.794
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen Griffiths; Naveed Sattar; Jaqueline P Smith; Deborah P M Symmons; Peter Nightingale; George S Metsios; George D Kitas Journal: Ann Rheum Dis Date: 2009-10-23 Impact factor: 19.103
Authors: V F Panoulas; K M J Douglas; H J Milionis; A Stavropoulos-Kalinglou; P Nightingale; M D Kita; A L Tselios; G S Metsios; M S Elisaf; G D Kitas Journal: Rheumatology (Oxford) Date: 2007-08-17 Impact factor: 7.580
Authors: Aimée Wattiaux; Brittany Bettendorf; Laura Block; Andrea Gilmore-Bykovskyi; Edmond Ramly; Megan E Piper; Ann Rosenthal; Jane Sadusky; Elizabeth Cox; Betty Chewning; Christie M Bartels Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Kashif Jafri; Christie M Bartels; Daniel Shin; Joel M Gelfand; Alexis Ogdie Journal: Arthritis Care Res (Hoboken) Date: 2016-11-28 Impact factor: 4.794
Authors: Dmitry Khodyakov; Sean Grant; Daniella Meeker; Marika Booth; Nathaly Pacheco-Santivanez; Katherine K Kim Journal: J Am Med Inform Assoc Date: 2017-05-01 Impact factor: 4.497
Authors: Christie M Bartels; Lauren Johnson; Edmond Ramly; Daniel J Panyard; Andrea Gilmore-Bykovskyi; Heather M Johnson; Patrick McBride; Zhanhai Li; Emmanuel Sampene; Diane R Lauver; Kristin Lewicki; Megan E Piper Journal: Arthritis Care Res (Hoboken) Date: 2022-05-27 Impact factor: 5.178